Correlation of Clinicopathological Features and Expression of Molecular Markers With Prognosis After 131I Treatment of Differentiated Thyroid Carcinoma

Abstract

Male gender, and lymph node and distant metastases were found to be poor prognostic factors for patients with DTC. Higher expressions of ER, PR, HER-2, EphA-2, and NIS were associated with DTC, but were not correlated with the effectiveness of radioiodine treatment.

HER2 Analysis in Sporadic Thyroid Cancer of Follicular Cell Origin

“…To date, many studies have evaluated HER2 expression in thyroid cancer with controversial results, largely due to inter-study differences in the size and setting of the examined series and, most of all, to the subjective assessment and lack of uniform methodology [14,15,16,17,18,19,20,21,22,23,24,25,26]. Indeed, studies reported in the literature in the past several decades markedly differ by the methodological approach used to assess HER2 status [14,15,16,17,18,19,20,21,22,23,24,25,26].…”

“…Studies on HER2 have also been performed in thyroid cancer cells and tissues [14,15,16,17,18,19,20,21,22,23,24,25,26]. Interestingly, a wide variation in HER2 overexpression was reported in such studies, with positivity rates varying from 0% up to 70%, which may largely be attributed to inter-study technical and interpretive variations.…”

“…Interestingly, a wide variation in HER2 overexpression was reported in such studies, with positivity rates varying from 0% up to 70%, which may largely be attributed to inter-study technical and interpretive variations. Due to these conflicting findings, there is no consensus in the currently available literature regarding the potential prognostic and therapeutic value of this marker in thyroid cancer [16,18,23,24]. More recently, HER2 expression has been linked to the expression of estrogen receptors in thyroid tumor tissue [27] and associated with BRAF V600E mutation and a more aggressive phenotype in familial papillary thyroid cancers (PTCs) [28].…”

PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells

“…Together with the well-differentiated forms, which are efficaciously managed by the treatment with surgery and radioiodine, an increased prevalence was reported also for the less differentiated carcinomas [1,3]. These tumors are unable to concentrate this radioisotope and do not respond to the standard treatment or develop radio resistance [4,5]. These unresponsive tumors are characterized by an altered phenotype, often including the reduction/loss of expression of sodium/iodide symporter (NIS) and thyroperoxidase (TPO), owing to the oncogenic activation of intracellular signal transduction pathways which control cell growth and differentiation [6][7][8][9].…”

Analysis of GPER1, CXCR1 and HER-2 Immuno Expression in Follicular Thyroid Lesions and their Possible Role as Diagnostic Markers

“…Previous studies have proposed that combining CXCR1 inhibitors with HER-2 targeted therapies can play a role in better survival during the treatment of HER-2 over expressing breast cancers [22,23]. In thyroid cancer, previous studies showed conflicting results with HER-2 positivity rates varying from 0% to 70% [24][25][26]. Moreover, HER-2 expression was linked to estrogen receptors expression in thyroid tumours [13].…”